We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
JAMA Clinical Guidelines Synopsis |

Management of Anticoagulation in Patients With Atrial Fibrillation

Joshua D. Moss, MD1; Adam S. Cifu, MD1
[+] Author Affiliations
1Department of Medicine, University of Chicago, Chicago, Illinois
JAMA. 2015;314(3):291-292. doi:10.1001/jama.2015.3088.
Text Size: A A A
Published online


This JAMA Clinical Guidelines Synopsis article summarizes the evidence for management of anticoagulation therapy in patients with atrial fibrillation.

Box Section Ref ID

Guideline title 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation (Section on Prevention of Thromboembolism)

Developers American College of Cardiology (ACC)/American Heart Association (AHA) in collaboration with the Society of Thoracic Surgeons

Release dates March 28, 2014 (online); December 2, 2014 (print)

Prior version August 15, 2006 (with focused updates January 4, 2011, and March 15, 2011)

Funding sources ACC, AHA

Target population All patients with atrial fibrillation (AF). This summary focuses on patients with nonvalvular AF.

Major recommendations

  • For nonvalvular AF that is paroxysmal, persistent, or permanent, oral anticoagulation is recommended for patients with prior stroke, transient ischemic attack, or a CHA2DS2-VASc score of 2 or greater (class I recommendation) using warfarin (level of evidence A) or a direct thrombin or factor Xa inhibitor (level of evidence B). Antithrombotic therapy should be managed the same way for atrial flutter (class I recommendation, level of evidence C). For patients with nonvalvular AF and a CHA2DS2-VASc score of 0, it is reasonable to omit antithrombotic therapy (class IIa recommendation, level of evidence B). For a CHA2DS2-VASc score of 1, treatment with an oral anticoagulant or aspirin may be considered.

  • In the setting of chronic kidney disease (CKD), warfarin should be used in the setting of a creatinine clearance less than 15 mL/min or hemodialysis (class IIa recommendation, level of evidence B); reduced doses of dabigatran, rivaroxaban, or apixaban may be considered for moderate to severe CKD (class IIb recommendation, level of evidence C). Dabigatran and rivaroxaban should not be used in patients with end-stage CKD (class III recommendation, no benefit).

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles